News & Updates
Filter by Specialty:
COPD, smoking aggravate complication risk after lung cancer resection
Smoking and chronic obstructive pulmonary disease (COPD) worsen the risk of postoperative pulmonary complications after lung cancer resection, a recent study has found. Focusing on COPD treatment, rather than smoking cessation alone, may be a more optimal approach to improve postoperative outcomes in this population.
COPD, smoking aggravate complication risk after lung cancer resection
03 Apr 2022
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
01 Apr 2022
T-DXd ups PFS vs T-DM1 in HER2-positive metastatic breast cancer
Trastuzumab deruxtecan (T-DXd) reduces the risk of disease progression or death by 72 percent vs trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer whose disease progressed during or after treatment with an anti–HER-2 antibody, the first interim analysis of the DESTINY-Breast03 trial has shown.
T-DXd ups PFS vs T-DM1 in HER2-positive metastatic breast cancer
01 Apr 2022
Exclusionary testing most efficient and cost-saving for NSCLC
Exclusionary testing, involving upfront testing for EGFR and ALK followed by next-generation sequencing (NGS) for other genomic alterations (GAs), is the most efficient and cost-saving molecular testing strategy for patients with metastatic non-small-cell lung cancer (NSCLC) in Hong Kong and perhaps East Asia, researchers from the Chinese University of Hong Kong (CUHK) have reported.
Exclusionary testing most efficient and cost-saving for NSCLC
01 Apr 2022
Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
Low-dose aspirin reduces risks of some common gastrointestinal (GI) cancers, including colorectal cancer (CRC) and gastric cancer (GC), in Chinese without atherosclerotic cardiovascular disease (ASCVD), compared with paracetamol, the first population-wide study from the University of Hong Kong (HKU) has shown.
Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
31 Mar 2022
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.